## **Special Issue**

# Protein Kinase Inhibitors for Targeted Anticancer Therapies, 2nd Edition

## Message from the Guest Editor

Dear Colleague, Protein kinase inhibitors are one of the most promising groups of drugs for targeted therapies. According to the latest data, 62 small-molecule protein kinase inhibitors have been approved by the Federal Drug Administration (FDA) (37 in the last 5 years), while at least 150 are currently being investigated in clinical trials. This is primarily due to a better understanding of the complex signaling network formed by kinases and their mutual relationships in signal transduction cascades. However, despite the growing number of inhibitors, many limitations remain in this field. The development of resistance based on intrinsic and extrinsic pathways, genomic alterations of the primary target, and a short response to targeted therapies due to the activation of compensatory signaling pathways are among the main issues. The aim of this Special Issue is to highlight original research papers and review articles that provide new insights into the discovery of novel protein kinase inhibitors, as well as their application in targeted cancer therapies.

## **Guest Editor**

Dr. Katarzyna Malarz

A. Chełkowski Institute of Physics and Silesian Center for Education and Interdisciplinary Research, University of Silesia in Katowice, 75 Pułku Piechoty 1, 41-500 Chorzów, Poland

#### Deadline for manuscript submissions

closed (30 June 2024)



an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/159537

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

#### Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

### **Author Benefits**

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

## **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

